Janet focuses on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Her clients range from large multinational biopharmaceutical companies, such as Celgene and Genentech, to emerging startup companies around the world. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. She has Ph.D. in Biological Chemistry from University of California, Los Angeles, and an M.S. in Molecular Biology and Protein Chemistry from the Institute of Biophysics, Chinese Academy of Science.
In this timely session, we will discuss latest patent law developments in the rapidly expanding field of immunotherapy. Topics will include patentability issues, recent case law, and patent strategy considerations. You will take away insights into how to navigate the evolving case law around immunotherapies and build valuable patent portfolios in light of these new developments.